Results 71 to 80 of about 13,248 (184)

Ceftazidime/avibactam in the era of carbapenemase-producing Klebsiella pneumoniae: Experience from a national registry study

, 2021
Background: Infections caused by KPC-producing Klebsiella pneumoniae (Kp) are associated with high mortality. Therefore, new treatment options are urgently required.
Giamarellou, H., Symbardi, S., Filiou, E., Adamis, G., Basoulis, D., Mouloudi, E., Karaiskos, I., ikaraiskos@hygeia.gr, Akinosoglou, K., Gkoufa, A., Masgala, A., Petraki, M., Stefos, A., Chrysos, G., Daikos, G.L., Galani, L., Papadimitriou, E., Poulakou, G., Routsi, C., Galani, I., Arvaniti, K., Karaiskos I., ikaraiskos@hygeia.gr, Daikos G.L., Gkoufa A., Adamis G., Stefos A., Symbardi S., Chrysos G., Filiou E., Basoulis D., Mouloudi E., Galani L., Akinosoglou K., Arvaniti K., Masgala A., Petraki M., Papadimitriou E., Galani I., Poulakou G., Routsi C., Giamarellou H.   +20 more
core   +2 more sources

Antibiotic‐Impregnated Calcium Sulfate Beads for Local Therapy of Severe Skull Base Osteomyelitis

Clinical Case Reports, Volume 14, Issue 6, June 2026.
Novel Local Therapy of Severe Skull Base Osteomyelitis. ABSTRACT We report on a patient with severe progressive osteomyelitis of the lateral skull base, despite targeted long‐term antibiotic therapy. Successful treatment and recovery of the facial nerve palsy were achieved through additional surgical debridement and insertion of synthetic calcium ...
Stefan Lyutenski, Aviva Henze, Paul James, Marc Bloching   +3 more
wiley   +1 more source

Inhibition of Klebsiella β-Lactamases (SHV-1 and KPC-2) by Avibactam: A Structural Study. [PDF]

, 2015
β-Lactamase inhibition is an important clinical strategy in overcoming β-lactamase-mediated resistance to β-lactam antibiotics in Gram negative bacteria.
Nhu Q Nguyen, Focco van den Akker, Nikhil P Krishnan, Krisztina M Papp-Wallace, Robert A Bonomo   +4 more
core   +1 more source

Ceftazidime-Avibactam: a Novel Cephalosporin/β-lactamase Inhibitor Combination

, 2013
Avibactam (formerly NXL104, AVE1330A) is a synthetic non-β-lactam, β-lactamase inhibitor that inhibits the activities of Ambler class A and C β-lactamases and some Ambler class D enzymes. This review summarizes the existing data published for ceftazidime-
Hoban, Daryl J., Zhanel, George G., Karlowsky, James A., Adam, Heather, Lawson, Christopher D., Schweizer, Frank, Gin, Alfred S., Lynch, Joseph P., Zelenitsky, Sheryl, Denisuik, Andrew, Rubinstein, Ethan, Lagacé-Wiens, Philippe R. S.   +11 more
core   +1 more source

Table_1_In Vitro Activity Comparison of Ceftazidime–Avibactam and Aztreonam–Avibactam Against Bloodstream Infections With Carbapenem-Resistant Organisms in China.docx

, 2021
ObjectivesThe aim of this work was to investigate the activity of ceftazidime–avibactam (CZA) and aztreonam–avibactam (AZA) against bloodstream infections caused by carbapenem-resistant organisms (CROs).MethodsNon-duplicate CROs, including 56 carbapenem ...
Jinru Ji (4023998), Wei Yu (43094), Chaoqun Ying (4024001), Zhiying Liu (350234), Qixia Luo (401575), Yonghong Xiao (248558), Luying Xiong (11755085), Yunbo Chen (739993)   +7 more
core   +1 more source

Allergic Reactions and Cross-Reactivity Potential with Beta-Lactamase Inhibitors

Pharmacy, 2019
Although beta-lactam allergies are an emerging focus of stewardship programs and interventions, less is publicly released regarding allergies to beta-lactamase inhibitors. This review presents and evaluates the data regarding allergic reactions with beta-
Kayla R. Stover, Katie E. Barber, Jamie L. Wagner   +2 more
doaj   +1 more source

Emergence of Fosfomycin Resistance Among ESBL‐Producing Escherichia coli in Abadan, Southwestern Iran

Health Science Reports, Volume 9, Issue 6, June 2026.
ABSTRACT Background and Aim Escherichia coli is a key pathogen responsible for various infections, such as urinary tract infections, gastroenteritis, and wound infections. The increasing occurrence of antimicrobial resistance, particularly in extended‐spectrum β‐lactamase (ESBL)‐producing strains, poses a significant global health threat.
Nabi Jomehzadeh, Ali Fakari
wiley   +1 more source

Ceftazidime-Avibactam for Carbapenem-Resistant Gram-Negative Bacteria Infections: A Real-World Experience in the ICU

, 2023
Jiaxin Yu,1,2 Wei Zuo,1,2 Hongwei Fan,1,3 Jiayu Wu,1,2 Luyao Qiao,1,2,4 Benyu Yang,1,2,5 Wenxi Li,1,2,5 Yang Yang,1,2,* Bo Zhang1,2,* 1Department of Pharmacy, Peking Union Medical College Hospital, Beijing, People’s Republic of China; 2State Key ...
Zuo W, Li W, Wu J, Fan H, Yang Y, Yang B, Yu J, Zhang B, Qiao L   +8 more
core  

The Role of Pharmacovigilance Database in Identifying Antibiotic Resistance and Inappropriate Use: An Analysis of VigiBase Reports From Lower‐Middle‐Income Countries

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 6, June 2026.
ABSTRACT Background Digital databases such as pharmacovigilance (PV) databases could provide unique opportunities to monitor trends in suspected antibiotic resistance, ineffectiveness, and misuse, extending beyond their traditional role of tracking adverse drug reactions (ADRs).
Hager Saleh, Joseph Mitchell, Cecilia Stålsby Lundborg, Megha Sharma   +3 more
wiley   +1 more source

Colistin Does Not Potentiate Ceftazidime-Avibactam Killing of Carbapenem-Resistant Enterobacteriaceae In Vitro or Suppress Emergence of Ceftazidime-Avibactam Resistance

, 2018
We tested ceftazidime-avibactam and colistin against 24 carbapenem-resistant Enterobacteriaceae (CRE) isolates by time-kill studies. Ceftazidime-avibactam at 0.25×, 1×, and 4× the MIC was bactericidal against 8%, 21%,
Binghua Hao, M. Hong Nguyen, Ryan K. Shields, Ellen G. Kline, Cornelius J. Clancy   +4 more
core   +1 more source